TY - JOUR
T1 - Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML
AU - Terwijn, Monique
AU - Feller, Nicole
AU - van Rhenen, Anna
AU - Kelder, Angèle
AU - Westra, Guus
AU - Zweegman, Sonja
AU - Ossenkoppele, Gert
AU - Schuurhuis, Gerrit Jan
N1 - Funding Information:
This work was supported by The Netherlands Cancer Foundation KWF Grant 2006-3695.
PY - 2009/6
Y1 - 2009/6
N2 - We investigated the role of CD25 as a prognostic marker in acute myeloid leukaemia (AML). Seventy-two newly diagnosed patients ≤60 years were retrospectively analysed by flow cytometry for CD25 positivity of AML blasts. Patients with CD25 expression of >10%, when compared to ≤10%, had a significantly shorter overall survival (OS, p = 0.0005) and relapse-free survival (RFS, p = 0.005). In multivariate analysis CD25 expression is an independent adverse factor for OS and RFS. High CD25 combined with FLT3-ITD positivity resulted in the poorest OS and RFS (p = 0.001 and p = 0.003, respectively). CD25 expression remained prognostic within the intermediate cytogenetic risk group. In addition, after the first cycle of chemotherapy, a significantly higher MRD frequency was found in patients expressing CD25 above cut-off (p = 0.003). Our results show that CD25 expression is an independent adverse prognostic marker in AML patients ≤60 and correlates with MRD.
AB - We investigated the role of CD25 as a prognostic marker in acute myeloid leukaemia (AML). Seventy-two newly diagnosed patients ≤60 years were retrospectively analysed by flow cytometry for CD25 positivity of AML blasts. Patients with CD25 expression of >10%, when compared to ≤10%, had a significantly shorter overall survival (OS, p = 0.0005) and relapse-free survival (RFS, p = 0.005). In multivariate analysis CD25 expression is an independent adverse factor for OS and RFS. High CD25 combined with FLT3-ITD positivity resulted in the poorest OS and RFS (p = 0.001 and p = 0.003, respectively). CD25 expression remained prognostic within the intermediate cytogenetic risk group. In addition, after the first cycle of chemotherapy, a significantly higher MRD frequency was found in patients expressing CD25 above cut-off (p = 0.003). Our results show that CD25 expression is an independent adverse prognostic marker in AML patients ≤60 and correlates with MRD.
KW - Acute myeloid leukaemia
KW - Flow cytometry
KW - IL-2 receptor
KW - Intermediate cytogenetics
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=66149095813&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2009.02.021
DO - 10.1016/j.ejca.2009.02.021
M3 - Article
C2 - 19321337
AN - SCOPUS:66149095813
SN - 0959-8049
VL - 45
SP - 1692
EP - 1699
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 9
ER -